nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosamprenavir—CYP3A4—Topotecan—ovarian cancer	0.202	0.354	CbGbCtD
Fosamprenavir—CYP3A4—Vinorelbine—ovarian cancer	0.143	0.249	CbGbCtD
Fosamprenavir—CYP3A4—Paclitaxel—ovarian cancer	0.1	0.175	CbGbCtD
Fosamprenavir—CYP3A4—Docetaxel—ovarian cancer	0.0725	0.127	CbGbCtD
Fosamprenavir—CYP3A4—Doxorubicin—ovarian cancer	0.054	0.0945	CbGbCtD
Fosamprenavir—Amprenavir—ABCB1—ovarian cancer	0.00262	1	CrCbGaD
Fosamprenavir—Neutropenia—Vinorelbine—ovarian cancer	0.0026	0.00611	CcSEcCtD
Fosamprenavir—Haemoglobin—Melphalan—ovarian cancer	0.00256	0.00601	CcSEcCtD
Fosamprenavir—Haemorrhage—Melphalan—ovarian cancer	0.00255	0.00598	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Melphalan—ovarian cancer	0.00251	0.00591	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Melphalan—ovarian cancer	0.0025	0.00588	CcSEcCtD
Fosamprenavir—Urethral disorder—Melphalan—ovarian cancer	0.0025	0.00586	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Vinorelbine—ovarian cancer	0.00244	0.00574	CcSEcCtD
Fosamprenavir—Myocardial infarction—Vinorelbine—ovarian cancer	0.00243	0.00571	CcSEcCtD
Fosamprenavir—Hyperlipidaemia—Epirubicin—ovarian cancer	0.00236	0.00555	CcSEcCtD
Fosamprenavir—Immune system disorder—Topotecan—ovarian cancer	0.00235	0.00552	CcSEcCtD
Fosamprenavir—Angioedema—Chlorambucil—ovarian cancer	0.00232	0.00546	CcSEcCtD
Fosamprenavir—Immune system disorder—Melphalan—ovarian cancer	0.0023	0.0054	CcSEcCtD
Fosamprenavir—Malnutrition—Topotecan—ovarian cancer	0.00226	0.00532	CcSEcCtD
Fosamprenavir—Hyperlipidaemia—Doxorubicin—ovarian cancer	0.00219	0.00514	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Vinorelbine—ovarian cancer	0.00219	0.00514	CcSEcCtD
Fosamprenavir—Angioedema—Topotecan—ovarian cancer	0.00207	0.00486	CcSEcCtD
Fosamprenavir—Cardiac disorder—Vinorelbine—ovarian cancer	0.00206	0.00485	CcSEcCtD
Fosamprenavir—Immune system disorder—Vinorelbine—ovarian cancer	0.00201	0.00472	CcSEcCtD
Fosamprenavir—Anorexia—Chlorambucil—ovarian cancer	0.00198	0.00465	CcSEcCtD
Fosamprenavir—Aspartate aminotransferase increased—Paclitaxel—ovarian cancer	0.00195	0.00458	CcSEcCtD
Fosamprenavir—Malnutrition—Vinorelbine—ovarian cancer	0.00194	0.00455	CcSEcCtD
Fosamprenavir—Myalgia—Topotecan—ovarian cancer	0.00193	0.00453	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Topotecan—ovarian cancer	0.00191	0.0045	CcSEcCtD
Fosamprenavir—Alanine aminotransferase increased—Paclitaxel—ovarian cancer	0.00191	0.00448	CcSEcCtD
Fosamprenavir—Myalgia—Melphalan—ovarian cancer	0.00189	0.00443	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Melphalan—ovarian cancer	0.00187	0.0044	CcSEcCtD
Fosamprenavir—Nervous system disorder—Topotecan—ovarian cancer	0.00181	0.00426	CcSEcCtD
Fosamprenavir—Decreased appetite—Chlorambucil—ovarian cancer	0.0018	0.00424	CcSEcCtD
Fosamprenavir—Skin disorder—Topotecan—ovarian cancer	0.00179	0.00422	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.00179	0.00421	CcSEcCtD
Fosamprenavir—Fatigue—Chlorambucil—ovarian cancer	0.00179	0.0042	CcSEcCtD
Fosamprenavir—Angioedema—Vinorelbine—ovarian cancer	0.00177	0.00416	CcSEcCtD
Fosamprenavir—Anorexia—Topotecan—ovarian cancer	0.00176	0.00414	CcSEcCtD
Fosamprenavir—Skin disorder—Melphalan—ovarian cancer	0.00176	0.00413	CcSEcCtD
Fosamprenavir—Inflammation—Epirubicin—ovarian cancer	0.00176	0.00413	CcSEcCtD
Fosamprenavir—Neutropenia—Paclitaxel—ovarian cancer	0.00175	0.00411	CcSEcCtD
Fosamprenavir—Anorexia—Melphalan—ovarian cancer	0.00172	0.00405	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.0017	0.00399	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Paclitaxel—ovarian cancer	0.00169	0.00396	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Topotecan—ovarian cancer	0.00168	0.00395	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Paclitaxel—ovarian cancer	0.00165	0.00388	CcSEcCtD
Fosamprenavir—Aspartate aminotransferase increased—Docetaxel—ovarian cancer	0.00165	0.00388	CcSEcCtD
Fosamprenavir—Myalgia—Vinorelbine—ovarian cancer	0.00165	0.00387	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Melphalan—ovarian cancer	0.00165	0.00387	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Paclitaxel—ovarian cancer	0.00164	0.00386	CcSEcCtD
Fosamprenavir—Abdominal pain—Chlorambucil—ovarian cancer	0.00164	0.00385	CcSEcCtD
Fosamprenavir—Body temperature increased—Chlorambucil—ovarian cancer	0.00164	0.00385	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.00164	0.00385	CcSEcCtD
Fosamprenavir—Myocardial infarction—Paclitaxel—ovarian cancer	0.00163	0.00384	CcSEcCtD
Fosamprenavir—Inflammation—Doxorubicin—ovarian cancer	0.00162	0.00382	CcSEcCtD
Fosamprenavir—Alanine aminotransferase increased—Docetaxel—ovarian cancer	0.00162	0.0038	CcSEcCtD
Fosamprenavir—Decreased appetite—Topotecan—ovarian cancer	0.00161	0.00377	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Topotecan—ovarian cancer	0.00159	0.00375	CcSEcCtD
Fosamprenavir—Fatigue—Topotecan—ovarian cancer	0.00159	0.00374	CcSEcCtD
Fosamprenavir—Decreased appetite—Melphalan—ovarian cancer	0.00157	0.00369	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Melphalan—ovarian cancer	0.00156	0.00367	CcSEcCtD
Fosamprenavir—Fatigue—Melphalan—ovarian cancer	0.00156	0.00366	CcSEcCtD
Fosamprenavir—Nervous system disorder—Vinorelbine—ovarian cancer	0.00155	0.00364	CcSEcCtD
Fosamprenavir—Skin disorder—Vinorelbine—ovarian cancer	0.00153	0.00361	CcSEcCtD
Fosamprenavir—Hypersensitivity—Chlorambucil—ovarian cancer	0.00153	0.00359	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Topotecan—ovarian cancer	0.00151	0.00355	CcSEcCtD
Fosamprenavir—Anorexia—Vinorelbine—ovarian cancer	0.00151	0.00354	CcSEcCtD
Fosamprenavir—Haemoglobin—Paclitaxel—ovarian cancer	0.0015	0.00353	CcSEcCtD
Fosamprenavir—Haemorrhage—Paclitaxel—ovarian cancer	0.0015	0.00352	CcSEcCtD
Fosamprenavir—Asthenia—Chlorambucil—ovarian cancer	0.00149	0.0035	CcSEcCtD
Fosamprenavir—Neutropenia—Docetaxel—ovarian cancer	0.00148	0.00348	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Paclitaxel—ovarian cancer	0.00148	0.00347	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Paclitaxel—ovarian cancer	0.00147	0.00345	CcSEcCtD
Fosamprenavir—Pruritus—Chlorambucil—ovarian cancer	0.00147	0.00345	CcSEcCtD
Fosamprenavir—Urethral disorder—Paclitaxel—ovarian cancer	0.00147	0.00345	CcSEcCtD
Fosamprenavir—Body temperature increased—Topotecan—ovarian cancer	0.00146	0.00343	CcSEcCtD
Fosamprenavir—Abdominal pain—Topotecan—ovarian cancer	0.00146	0.00343	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.00144	0.00338	CcSEcCtD
Fosamprenavir—Diabetes mellitus—Epirubicin—ovarian cancer	0.00142	0.00334	CcSEcCtD
Fosamprenavir—Diarrhoea—Chlorambucil—ovarian cancer	0.00142	0.00334	CcSEcCtD
Fosamprenavir—Erythema multiforme—Paclitaxel—ovarian cancer	0.00141	0.00332	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Docetaxel—ovarian cancer	0.0014	0.00329	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Docetaxel—ovarian cancer	0.00139	0.00327	CcSEcCtD
Fosamprenavir—Cardiac disorder—Paclitaxel—ovarian cancer	0.00139	0.00326	CcSEcCtD
Fosamprenavir—Myocardial infarction—Docetaxel—ovarian cancer	0.00138	0.00325	CcSEcCtD
Fosamprenavir—Decreased appetite—Vinorelbine—ovarian cancer	0.00137	0.00323	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.00136	0.00321	CcSEcCtD
Fosamprenavir—Fatigue—Vinorelbine—ovarian cancer	0.00136	0.0032	CcSEcCtD
Fosamprenavir—Hypersensitivity—Topotecan—ovarian cancer	0.00136	0.0032	CcSEcCtD
Fosamprenavir—Immune system disorder—Paclitaxel—ovarian cancer	0.00135	0.00318	CcSEcCtD
Fosamprenavir—Hypersensitivity—Melphalan—ovarian cancer	0.00133	0.00313	CcSEcCtD
Fosamprenavir—Asthenia—Topotecan—ovarian cancer	0.00133	0.00311	CcSEcCtD
Fosamprenavir—Vomiting—Chlorambucil—ovarian cancer	0.00132	0.0031	CcSEcCtD
Fosamprenavir—Diabetes mellitus—Doxorubicin—ovarian cancer	0.00132	0.00309	CcSEcCtD
Fosamprenavir—Pruritus—Topotecan—ovarian cancer	0.00131	0.00307	CcSEcCtD
Fosamprenavir—Malnutrition—Paclitaxel—ovarian cancer	0.0013	0.00306	CcSEcCtD
Fosamprenavir—Asthenia—Melphalan—ovarian cancer	0.0013	0.00305	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.00129	0.00304	CcSEcCtD
Fosamprenavir—Flatulence—Paclitaxel—ovarian cancer	0.00128	0.00302	CcSEcCtD
Fosamprenavir—Pruritus—Melphalan—ovarian cancer	0.00128	0.00301	CcSEcCtD
Fosamprenavir—Haemoglobin—Docetaxel—ovarian cancer	0.00127	0.00299	CcSEcCtD
Fosamprenavir—Haemorrhage—Docetaxel—ovarian cancer	0.00127	0.00298	CcSEcCtD
Fosamprenavir—Diarrhoea—Topotecan—ovarian cancer	0.00126	0.00297	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Docetaxel—ovarian cancer	0.00125	0.00294	CcSEcCtD
Fosamprenavir—Abdominal pain—Vinorelbine—ovarian cancer	0.00125	0.00294	CcSEcCtD
Fosamprenavir—Body temperature increased—Vinorelbine—ovarian cancer	0.00125	0.00294	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Docetaxel—ovarian cancer	0.00125	0.00293	CcSEcCtD
Fosamprenavir—Urethral disorder—Docetaxel—ovarian cancer	0.00124	0.00292	CcSEcCtD
Fosamprenavir—Diarrhoea—Melphalan—ovarian cancer	0.00124	0.00291	CcSEcCtD
Fosamprenavir—Nausea—Chlorambucil—ovarian cancer	0.00123	0.0029	CcSEcCtD
Fosamprenavir—Dizziness—Topotecan—ovarian cancer	0.00122	0.00287	CcSEcCtD
Fosamprenavir—Erythema multiforme—Docetaxel—ovarian cancer	0.0012	0.00282	CcSEcCtD
Fosamprenavir—Angioedema—Paclitaxel—ovarian cancer	0.00119	0.0028	CcSEcCtD
Fosamprenavir—Cardiac disorder—Docetaxel—ovarian cancer	0.00118	0.00277	CcSEcCtD
Fosamprenavir—Vomiting—Topotecan—ovarian cancer	0.00117	0.00276	CcSEcCtD
Fosamprenavir—Rash—Topotecan—ovarian cancer	0.00116	0.00274	CcSEcCtD
Fosamprenavir—Hypersensitivity—Vinorelbine—ovarian cancer	0.00116	0.00274	CcSEcCtD
Fosamprenavir—Dermatitis—Topotecan—ovarian cancer	0.00116	0.00273	CcSEcCtD
Fosamprenavir—Headache—Topotecan—ovarian cancer	0.00116	0.00272	CcSEcCtD
Fosamprenavir—Vomiting—Melphalan—ovarian cancer	0.00115	0.0027	CcSEcCtD
Fosamprenavir—Immune system disorder—Docetaxel—ovarian cancer	0.00115	0.00269	CcSEcCtD
Fosamprenavir—Rash—Melphalan—ovarian cancer	0.00114	0.00268	CcSEcCtD
Fosamprenavir—Dermatitis—Melphalan—ovarian cancer	0.00114	0.00268	CcSEcCtD
Fosamprenavir—Asthenia—Vinorelbine—ovarian cancer	0.00113	0.00266	CcSEcCtD
Fosamprenavir—Pruritus—Vinorelbine—ovarian cancer	0.00112	0.00263	CcSEcCtD
Fosamprenavir—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.00111	0.00262	CcSEcCtD
Fosamprenavir—Myalgia—Paclitaxel—ovarian cancer	0.00111	0.00261	CcSEcCtD
Fosamprenavir—Malnutrition—Docetaxel—ovarian cancer	0.0011	0.00259	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.0011	0.00259	CcSEcCtD
Fosamprenavir—Nausea—Topotecan—ovarian cancer	0.0011	0.00258	CcSEcCtD
Fosamprenavir—Gastritis—Epirubicin—ovarian cancer	0.00109	0.00257	CcSEcCtD
Fosamprenavir—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.00109	0.00256	CcSEcCtD
Fosamprenavir—Diarrhoea—Vinorelbine—ovarian cancer	0.00108	0.00254	CcSEcCtD
Fosamprenavir—Nausea—Melphalan—ovarian cancer	0.00107	0.00252	CcSEcCtD
Fosamprenavir—Dizziness—Vinorelbine—ovarian cancer	0.00104	0.00246	CcSEcCtD
Fosamprenavir—Nervous system disorder—Paclitaxel—ovarian cancer	0.00104	0.00245	CcSEcCtD
Fosamprenavir—Skin disorder—Paclitaxel—ovarian cancer	0.00103	0.00243	CcSEcCtD
Fosamprenavir—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.00103	0.00242	CcSEcCtD
Fosamprenavir—Anorexia—Paclitaxel—ovarian cancer	0.00101	0.00238	CcSEcCtD
Fosamprenavir—Gastritis—Doxorubicin—ovarian cancer	0.00101	0.00238	CcSEcCtD
Fosamprenavir—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.00101	0.00237	CcSEcCtD
Fosamprenavir—Vomiting—Vinorelbine—ovarian cancer	0.001	0.00236	CcSEcCtD
Fosamprenavir—Neutropenia—Epirubicin—ovarian cancer	0.000999	0.00235	CcSEcCtD
Fosamprenavir—Rash—Vinorelbine—ovarian cancer	0.000996	0.00234	CcSEcCtD
Fosamprenavir—Dermatitis—Vinorelbine—ovarian cancer	0.000995	0.00234	CcSEcCtD
Fosamprenavir—Headache—Vinorelbine—ovarian cancer	0.00099	0.00233	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000968	0.00228	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Epirubicin—ovarian cancer	0.000964	0.00226	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000944	0.00222	CcSEcCtD
Fosamprenavir—Myalgia—Docetaxel—ovarian cancer	0.00094	0.00221	CcSEcCtD
Fosamprenavir—Nausea—Vinorelbine—ovarian cancer	0.000939	0.00221	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000933	0.00219	CcSEcCtD
Fosamprenavir—Neutropenia—Doxorubicin—ovarian cancer	0.000924	0.00217	CcSEcCtD
Fosamprenavir—Decreased appetite—Paclitaxel—ovarian cancer	0.000924	0.00217	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000918	0.00216	CcSEcCtD
Fosamprenavir—Fatigue—Paclitaxel—ovarian cancer	0.000916	0.00215	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000892	0.0021	CcSEcCtD
Fosamprenavir—Nervous system disorder—Docetaxel—ovarian cancer	0.000883	0.00208	CcSEcCtD
Fosamprenavir—Skin disorder—Docetaxel—ovarian cancer	0.000875	0.00206	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000874	0.00205	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000869	0.00204	CcSEcCtD
Fosamprenavir—Haemoglobin—Epirubicin—ovarian cancer	0.00086	0.00202	CcSEcCtD
Fosamprenavir—Anorexia—Docetaxel—ovarian cancer	0.000859	0.00202	CcSEcCtD
Fosamprenavir—Haemorrhage—Epirubicin—ovarian cancer	0.000855	0.00201	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Epirubicin—ovarian cancer	0.000845	0.00198	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Epirubicin—ovarian cancer	0.00084	0.00197	CcSEcCtD
Fosamprenavir—Body temperature increased—Paclitaxel—ovarian cancer	0.00084	0.00197	CcSEcCtD
Fosamprenavir—Abdominal pain—Paclitaxel—ovarian cancer	0.00084	0.00197	CcSEcCtD
Fosamprenavir—Urethral disorder—Epirubicin—ovarian cancer	0.000838	0.00197	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000821	0.00193	CcSEcCtD
Fosamprenavir—Erythema multiforme—Epirubicin—ovarian cancer	0.000809	0.0019	CcSEcCtD
Fosamprenavir—Haemoglobin—Doxorubicin—ovarian cancer	0.000795	0.00187	CcSEcCtD
Fosamprenavir—Cardiac disorder—Epirubicin—ovarian cancer	0.000794	0.00187	CcSEcCtD
Fosamprenavir—Haemorrhage—Doxorubicin—ovarian cancer	0.000791	0.00186	CcSEcCtD
Fosamprenavir—Decreased appetite—Docetaxel—ovarian cancer	0.000783	0.00184	CcSEcCtD
Fosamprenavir—Hypersensitivity—Paclitaxel—ovarian cancer	0.000783	0.00184	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000781	0.00184	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000778	0.00183	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000778	0.00183	CcSEcCtD
Fosamprenavir—Fatigue—Docetaxel—ovarian cancer	0.000777	0.00183	CcSEcCtD
Fosamprenavir—Urethral disorder—Doxorubicin—ovarian cancer	0.000776	0.00182	CcSEcCtD
Fosamprenavir—Immune system disorder—Epirubicin—ovarian cancer	0.000772	0.00182	CcSEcCtD
Fosamprenavir—Asthenia—Paclitaxel—ovarian cancer	0.000763	0.00179	CcSEcCtD
Fosamprenavir—Pruritus—Paclitaxel—ovarian cancer	0.000752	0.00177	CcSEcCtD
Fosamprenavir—Erythema multiforme—Doxorubicin—ovarian cancer	0.000748	0.00176	CcSEcCtD
Fosamprenavir—Malnutrition—Epirubicin—ovarian cancer	0.000744	0.00175	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000737	0.00173	CcSEcCtD
Fosamprenavir—Cardiac disorder—Doxorubicin—ovarian cancer	0.000734	0.00173	CcSEcCtD
Fosamprenavir—Flatulence—Epirubicin—ovarian cancer	0.000734	0.00172	CcSEcCtD
Fosamprenavir—Diarrhoea—Paclitaxel—ovarian cancer	0.000727	0.00171	CcSEcCtD
Fosamprenavir—Immune system disorder—Doxorubicin—ovarian cancer	0.000715	0.00168	CcSEcCtD
Fosamprenavir—Abdominal pain—Docetaxel—ovarian cancer	0.000712	0.00167	CcSEcCtD
Fosamprenavir—Body temperature increased—Docetaxel—ovarian cancer	0.000712	0.00167	CcSEcCtD
Fosamprenavir—Dizziness—Paclitaxel—ovarian cancer	0.000703	0.00165	CcSEcCtD
Fosamprenavir—Malnutrition—Doxorubicin—ovarian cancer	0.000689	0.00162	CcSEcCtD
Fosamprenavir—Flatulence—Doxorubicin—ovarian cancer	0.000679	0.0016	CcSEcCtD
Fosamprenavir—Vomiting—Paclitaxel—ovarian cancer	0.000676	0.00159	CcSEcCtD
Fosamprenavir—Rash—Paclitaxel—ovarian cancer	0.00067	0.00157	CcSEcCtD
Fosamprenavir—Dermatitis—Paclitaxel—ovarian cancer	0.000669	0.00157	CcSEcCtD
Fosamprenavir—Headache—Paclitaxel—ovarian cancer	0.000666	0.00156	CcSEcCtD
Fosamprenavir—Hypersensitivity—Docetaxel—ovarian cancer	0.000664	0.00156	CcSEcCtD
Fosamprenavir—Asthenia—Docetaxel—ovarian cancer	0.000646	0.00152	CcSEcCtD
Fosamprenavir—Pruritus—Docetaxel—ovarian cancer	0.000637	0.0015	CcSEcCtD
Fosamprenavir—Myalgia—Epirubicin—ovarian cancer	0.000634	0.00149	CcSEcCtD
Fosamprenavir—Nausea—Paclitaxel—ovarian cancer	0.000631	0.00148	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000629	0.00148	CcSEcCtD
Fosamprenavir—Diarrhoea—Docetaxel—ovarian cancer	0.000616	0.00145	CcSEcCtD
Fosamprenavir—Nervous system disorder—Epirubicin—ovarian cancer	0.000596	0.0014	CcSEcCtD
Fosamprenavir—Dizziness—Docetaxel—ovarian cancer	0.000596	0.0014	CcSEcCtD
Fosamprenavir—Skin disorder—Epirubicin—ovarian cancer	0.00059	0.00139	CcSEcCtD
Fosamprenavir—Myalgia—Doxorubicin—ovarian cancer	0.000586	0.00138	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000582	0.00137	CcSEcCtD
Fosamprenavir—Anorexia—Epirubicin—ovarian cancer	0.000579	0.00136	CcSEcCtD
Fosamprenavir—Vomiting—Docetaxel—ovarian cancer	0.000573	0.00135	CcSEcCtD
Fosamprenavir—Rash—Docetaxel—ovarian cancer	0.000568	0.00133	CcSEcCtD
Fosamprenavir—Dermatitis—Docetaxel—ovarian cancer	0.000567	0.00133	CcSEcCtD
Fosamprenavir—Headache—Docetaxel—ovarian cancer	0.000564	0.00133	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000554	0.0013	CcSEcCtD
Fosamprenavir—Nervous system disorder—Doxorubicin—ovarian cancer	0.000551	0.0013	CcSEcCtD
Fosamprenavir—Skin disorder—Doxorubicin—ovarian cancer	0.000546	0.00128	CcSEcCtD
Fosamprenavir—Anorexia—Doxorubicin—ovarian cancer	0.000536	0.00126	CcSEcCtD
Fosamprenavir—Nausea—Docetaxel—ovarian cancer	0.000535	0.00126	CcSEcCtD
Fosamprenavir—Decreased appetite—Epirubicin—ovarian cancer	0.000528	0.00124	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000525	0.00123	CcSEcCtD
Fosamprenavir—Fatigue—Epirubicin—ovarian cancer	0.000524	0.00123	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000512	0.0012	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000497	0.00117	CcSEcCtD
Fosamprenavir—Decreased appetite—Doxorubicin—ovarian cancer	0.000489	0.00115	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000485	0.00114	CcSEcCtD
Fosamprenavir—Fatigue—Doxorubicin—ovarian cancer	0.000485	0.00114	CcSEcCtD
Fosamprenavir—Body temperature increased—Epirubicin—ovarian cancer	0.00048	0.00113	CcSEcCtD
Fosamprenavir—Abdominal pain—Epirubicin—ovarian cancer	0.00048	0.00113	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.00046	0.00108	CcSEcCtD
Fosamprenavir—Hypersensitivity—Epirubicin—ovarian cancer	0.000448	0.00105	CcSEcCtD
Fosamprenavir—Abdominal pain—Doxorubicin—ovarian cancer	0.000444	0.00104	CcSEcCtD
Fosamprenavir—Body temperature increased—Doxorubicin—ovarian cancer	0.000444	0.00104	CcSEcCtD
Fosamprenavir—Asthenia—Epirubicin—ovarian cancer	0.000436	0.00102	CcSEcCtD
Fosamprenavir—Pruritus—Epirubicin—ovarian cancer	0.00043	0.00101	CcSEcCtD
Fosamprenavir—Diarrhoea—Epirubicin—ovarian cancer	0.000416	0.000977	CcSEcCtD
Fosamprenavir—Hypersensitivity—Doxorubicin—ovarian cancer	0.000414	0.000973	CcSEcCtD
Fosamprenavir—Asthenia—Doxorubicin—ovarian cancer	0.000403	0.000948	CcSEcCtD
Fosamprenavir—Dizziness—Epirubicin—ovarian cancer	0.000402	0.000944	CcSEcCtD
Fosamprenavir—Pruritus—Doxorubicin—ovarian cancer	0.000398	0.000935	CcSEcCtD
Fosamprenavir—Vomiting—Epirubicin—ovarian cancer	0.000386	0.000908	CcSEcCtD
Fosamprenavir—Diarrhoea—Doxorubicin—ovarian cancer	0.000385	0.000904	CcSEcCtD
Fosamprenavir—Rash—Epirubicin—ovarian cancer	0.000383	0.0009	CcSEcCtD
Fosamprenavir—Dermatitis—Epirubicin—ovarian cancer	0.000383	0.000899	CcSEcCtD
Fosamprenavir—Headache—Epirubicin—ovarian cancer	0.000381	0.000895	CcSEcCtD
Fosamprenavir—Dizziness—Doxorubicin—ovarian cancer	0.000372	0.000874	CcSEcCtD
Fosamprenavir—Nausea—Epirubicin—ovarian cancer	0.000361	0.000848	CcSEcCtD
Fosamprenavir—Vomiting—Doxorubicin—ovarian cancer	0.000357	0.00084	CcSEcCtD
Fosamprenavir—Rash—Doxorubicin—ovarian cancer	0.000354	0.000833	CcSEcCtD
Fosamprenavir—Dermatitis—Doxorubicin—ovarian cancer	0.000354	0.000832	CcSEcCtD
Fosamprenavir—Headache—Doxorubicin—ovarian cancer	0.000352	0.000828	CcSEcCtD
Fosamprenavir—Nausea—Doxorubicin—ovarian cancer	0.000334	0.000785	CcSEcCtD
